Referring DoctorsYou may refer patients to our office by filling out our secure online Referral Form. After you have completed the form, please make sure to press the Submit button at the bottom to automatically send us your information. The security and privacy of patient data is one of our primary concerns and we have taken every precaution to protect it. |
 |
 |
RESEARCH AND PRESENTATIONS
Bisphosphonates and Jaw Necrosis
Click Here to review Dr. Barsan's slides for the September 12, 2006 presentation "Bisphosphonate-associated Osteonecrosis of the Jaws (BON).
Downloadable Files (PDF)
- Dr. Durie's presentation on Osteonecrosis of the Jaws at the International Myeloma Foundation
- Information for patients about Osteonecrosis of the jaw and bisphosphonsate drugs by the Paget's Foundation
- Fosamax (Alendronate Sodium) Prescribing information-Merck & Co, Inc.
- Web Seminar, Amer Assoc of Oral & Maxillofacial Surg - Osteoporosis and Dental Health
- International Myeloma Foundation Patient Brochure, "Taking Care of Yourself While Living With Cancer"
Technical Note: You need Adobe Acrobat Reader to view PDF document. Please download the free Acrobat Reader from Adobe's web site if it is not already installed on your system.
References
American Dental Association:
http://www.ada.org/prof/resources/topics/osteonecrosis.asp
International Myeloma Foundation:
Osteonecrosis of the jaws in myeloma: time dependent correlation with Aredia® and Zometa® use
Aredia®/Zometa® and osteonecrosis of the jaws, A new update-July, 2004
American Association of Oral and Maxillofacial Surgeons:
Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws-September 25, 2006
Literature:
Bamias A, Kastritis E, Bamia C, Moulopoulos LA, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-8587
Hellman JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-689
Lacy MQ, Dispenzieri A, Gertz MA, Griepp PR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81(8):1047-1053
Letters to the editor: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353(1):99-102
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575
Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer . 2005;104(1):83-93
Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S-B. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Amer Dental Assoc 2005;136:1658-68
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34
Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V. Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer. J Oncol Prac 2006;2:7-14
VanPoznak C, Etilo C, Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates, Oncology (Special Issue)2006;20(9):1053-1062
Woo S-B, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:100